Literature DB >> 7923130

The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase.

R S Chapman1, A D Whetton, C Dive.   

Abstract

Cells with a temperature-sensitive mutant of the v-abl oncoprotein (IC.DP) were treated with the anticancer drugs melphalan or hydroxyurea. At the restrictive temperature for v-ABL protein tyrosine kinase activity, drug-treated IC.DP cells died by apoptosis. In contrast, apoptotic cell death induced by either drug was suppressed when v-ABL was active. However, melphalan-induced accumulation of cells in the S and G2-M phases of the cell cycle was unaffected by v-ABL activation. Moreover, the continuous presence of v-ABL activity was necessary to suppress apoptosis. This suggested that melphalan had interacted with DNA and that v-ABL activity prevented the coupling of drug-induced damage to the apoptotic pathway. IC.DP cells exhibited similar levels and subcellular localization of the BCL-2 protein irrespective of v-ABL activation status, thus v-ABL-mediated cell survival appeared to be independent of BCL-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923130

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.

Authors:  E M Weissinger; G Eissner; C Grammer; S Fackler; B Haefner; L S Yoon; K S Lu; A Bazarov; J M Sedivy; H Mischak; W Kolch
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

Review 2.  Mechanisms of drug resistance in colon cancer and its therapeutic strategies.

Authors:  Tao Hu; Zhen Li; Chun-Ying Gao; Chi Hin Cho
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

3.  Apoptosis resistance in tumor cells.

Authors:  T Mashima; H Seimiya; Z Chen; S Kataoka; T Tsuruo
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

4.  Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells via ROS Regulation.

Authors:  Chao Zhang; Lian-Jun He; Yi-Bao Zhu; Qing-Zhu Fan; Dong-Dong Miao; Sheng-Peng Zhang; Wen-Ying Zhao; Xiao-Ping Liu
Journal:  Front Pharmacol       Date:  2019-10-11       Impact factor: 5.810

5.  Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line.

Authors:  Chao Zhang; Lian-Jun He; Hai-Zhu Ye; Ding-Feng Liu; Yi-Bao Zhu; Dong-Dong Miao; Sheng-Peng Zhang; Yun-Yu Chen; Yuan-Wei Jia; Jie Shen; Xiao-Ping Liu
Journal:  Mol Med Rep       Date:  2018-10-24       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.